| Name of disease |
New symptoms after COVID-19 |
Hospitalization due to COVID-19 |
COVID-19 related mortality |
| Stroke |
Anosmia, fatigue, dizziness, headache, and myalgia; Dizziness, Headache, Confusion, Altered mental status, Facial droop, Slurred speech, weakness, and Paralysis; Difficulties in memory, poor concentration, visual disturbance, decreased consciousness levels, seizures, delirium, involuntary movements, and ataxia |
Duration of hospital stay was generally increased. |
COVID-19 patients with stroke had higher chances of worse outcomes and more significant mortality than those without. |
| Parkinson’s disease (PD) |
Exaggeration of motor symptoms was more common than non-motor symptoms |
Increased hospitalization and ICU admission rate among known Parkinson’s patients |
Higher mortality rate compared to patients with no neurologic disorders |
| Delirium |
Not related to developing new symptoms. |
Patients previously diagnosed with dementia are more likely to develop delirium and less likely to exhibit some other COVID-19 symptoms on presentation. |
Delirium associated with COVID-19 has been associated with increased mortality. |
| Alzheimer’s disease (AD) |
Neuro-degeneration, Cognitive decline memory deterioration, behavioral changes, orientation abilities, reduced levels of independence, functional decline, and new or deteriorating behavioral disturbances, including aggression, apathy, and depression |
People with Alzheimer's Disease are at high risk of contracting COVID-19 and develop worsening outcome |
Increased risk of mortality |
| Multiple sclerosis (MS) |
Multiple Sclerosis exacerbation or recrudescence or additional signs not typical of MS |
Increased in Progressive MS subtype or presence of other comorbidities |
Not increased |
| Epilepsy |
Headache, Myalgia, Delirium, Parageusia, Anosmia, Limb weakness, Distorted mental status after withdrawal of sedatives, |
Not increased |
Increased risk of mortality and sudden unexpected death. |
